mtx-101
Small moleculeexperimentalBi-specific
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 30, 2024 (NCT06324604)
Timeline
Indications
Mechanism of action
KIR2DL1 inhibitor
CD8A inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes (Bi-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06728553 | Phase 2 | Feb 28, 2025 | Manistee Therapeutics, Sponsor GmbH |
| NCT06324604 | Phase 1 | Jun 30, 2024 | Mozart Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Manistee Therapeutics | For profit | 1 | 1 | 1 | 2025 |
| Mozart Therapeutics | For profit | 1 | 1 | 1 | 2024 |
| Sponsor GmbH | Academic/Hospital | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1